FOX J P, KOPROWSKI H, CONWELL D P, BLACK J, GELFAND H M
Bull World Health Organ. 1957;17(6):869-904.
Detailed results are presented of primary immunizations of 387 persons with various courses of HEP Flury vaccine and of 54 persons with Harris- or Semple-type vaccines. Antibody response to HEP Flury vaccine was at least as rapid as that to the conventional type, but fell short in uniformity and level of response. The most promising course involved a 4-dose schedule, intradermal alone or combined with intramuscular, at 5-day intervals. A similar subcutaneous course of Semple vaccine yielded results completely equivalent to those of a 14-dose course of Harris vaccine. It is concluded that, although living, the HEP Flury virus does not multiply in man and that its lesser antigenic potency, as compared with Semple or Harris vaccines, is due to its relatively small content of viral antigen.Further evidence has been obtained that hyperimmune serum may exert a slight suppressive effect on active response, but the opinion is expressed that, with vaccines of full potency, this will not be of practical significance.Restimulation of immunity by a booster dose of HEP Flury vaccine was studied in 64 experimentally immunized persons and in 136 persons with history of previous Pasteur treatment. In both instances small intradermal inocula were as effective as larger intramuscular inocula in recalling pre-existing immunity.Study of recipients of Pasteur treatment indicated that antibody commonly persists for at least 5 years after a single course and for 15 or more years after re-treatment. It was also observed that the ability to respond to a booster of HEP Flury vaccine persists for at least 25 years. The response elicited by the booster is prompt and is usually at least equal to that resulting from a full primary course. The suggested conclusion is that previously treated persons need not receive more than a single booster on re-exposure, and that Pasteur treatment provides a solid basis for long-sustained immunity.
本文详细介绍了387名接种不同疗程HEP Flury疫苗以及54名接种Harris型或Semple型疫苗的人员的初次免疫结果。HEP Flury疫苗的抗体反应至少与传统类型疫苗一样迅速,但在反应的均匀性和水平上有所不足。最有前景的疗程是采用4剂方案,仅皮内接种或皮内与肌肉注射相结合,间隔5天。类似的Semple疫苗皮下接种疗程产生的结果与Harris疫苗14剂疗程的结果完全相同。得出的结论是,尽管HEP Flury病毒是活病毒,但它不在人体中繁殖,与Semple或Harris疫苗相比,其抗原效力较低是由于其病毒抗原含量相对较少。还获得了进一步的证据,即超免疫血清可能对主动反应产生轻微的抑制作用,但有人认为,对于效力充分的疫苗,这在实际中不会具有重要意义。在64名经实验免疫的人员和136名有既往巴斯德治疗史的人员中研究了HEP Flury疫苗加强剂量对免疫的再刺激作用。在这两种情况下,小剂量皮内接种在唤起既往免疫方面与大剂量肌肉接种一样有效。对接受巴斯德治疗者的研究表明,抗体通常在单次疗程后至少持续5年,在再次治疗后持续15年或更长时间。还观察到,对HEP Flury疫苗加强剂作出反应的能力至少持续25年。加强剂引发的反应迅速,通常至少与完整初次疗程产生的反应相当。建议的结论是,既往接受过治疗的人员再次接触时无需接种超过一剂加强剂,并且巴斯德治疗为长期持续免疫提供了坚实的基础。